Biobran

Can a synergistic activation of pattern recognition receptors by plant immunomodulators enhance the effect of oncologic therapy? Case Report of a patient with uterus and ovary sarcoma. (Presented by Tibor Hajto, Lilla Baranyai, Angelika Kirsch, Monika Kuzma and Pal Perjési

admin — Fri, 21 Aug 2026 18:00:02 +0000

Breast Cancer Case Study 6 (Australia)

admin — Fri, 21 Aug 2026 17:56:44 +0000

Breast Cancer Case Study 7 (Australia)

admin — Fri, 21 Aug 2026 17:55:53 +0000

Prostate Cancer Case Study 2 (Australia)

admin — Fri, 21 Aug 2026 17:52:05 +0000

Prostate Cancer Case Study 3 (Australia)

admin — Fri, 21 Aug 2026 17:49:14 +0000

Can standardized and evidence based plant immunomodulator (rice bran arabinoxylan concentrate) increase the effect of Gemcitabine in a synergistic manner? Case report of a patient with ductal pancreas carcinoma (presented by Prof. Tibor Hajto)

admin — Fri, 21 Aug 2026 16:49:44 +0000

Basophilic Response in Patients with Persistent Symptoms Attributed to Lyme Borreliosis Treated with Hydrolysed Arabinoxylan Rice Bran

admin — Sat, 16 Aug 2025 20:11:00 +0000

Background and Objectives: MGN-3/Biobran (BRM4, Lentin Plus or Ribraxx) is a natural, rice bran-derived arabinoxylan immunoceutical that modulates the adaptive immune response to viral infections. In response to bacterial infections, basophils act as “first responders” and are also associated with modulation of the adaptive immune response. The maturation of pluripotent CD34+ stem cells into basophils is supported by the cytokine interleukin-3 (IL-3). The aim was to test the hypothesis that modulation of the adaptive immune response in bacterial infection by MGN-3/Biobran entails a basophilic response. The tick-related disorder Lyme borreliosis was chosen as the disease model; tick bites are associated with cutaneous IL-3-mediated basophil recruitment.

Materials and Methods: A three-month randomised double-blind placebo-controlled trial was conducted in patients with a history of borreliosis who were suffering from symptoms attributable to this disorder. The immunoceutical group received oral Biobran; the dosage for both groups was 1 g thrice daily. Both groups were matched for age, sex, and ethnicity. Results: A higher percentage of basophil count occurred in the immunoceutical group (p = 0.038). The final general linear model included the group (immunoceutical/placebo) and change in fatigue assessed by the 11-item Chalder Fatigue Questionnaire (CFQ) (r2 = 0.63; p = 0.0066). The change in basophil count was positively correlated with CFQ change (rs = 0.633; p = 0.020); only the immunoceutical group showed a positive correlation.

Conclusions: These results support the hypothesis being tested. Basophils may modulate the adaptive immune response by acting as immunoregulatory cells. They can regulate the functioning of type 2 T-helper lymphocytes, enhance immunological memory, and present antigens to CD8 T lymphocytes. Further studies are needed to clarify potential mechanistic factors and the timing of this basophilic response

Nanoparticle Enhanced. The Protective Effects of MGN-3 BioBran Against Ehrlich Ascites Carcinoma-Induced Toxicity in the Liver, Kidneys and Spleen of Mice

admin — Sat, 16 Aug 2025 20:09:00 +0000

Background: Nanoparticle-enabled targeted drug delivery has proven effective in cancer treatment due to its ability to cross biological barriers, achieve therapeutic concentrations within tumors, and minimize adverse effects on surrounding healthy tissues. MGN-3/Biobran is a widely recognized natural compound known for its anti-inflammatory, antioxidant, and anti-carcinogenic properties. This study examined the effects of natural product MGN-3 nanoparticles on the toxicity to liver, kidney and spleen caused by Ehrlich ascites cancer (EAC) in an in vivo model. Method: In addition to the negative control group, the EAC model was conducted by injecting EAC cells subcutaneously into the female albino mice’s thighs. Free MGN-3 and MGN-3 nanoparticles were injected intraperitoneally every other day into mice with solid Ehrlich carcinoma (SEC) tumors. Body weight (BW) was monitored throughout the study and tumors were collected on day 22 post-inoculation and weighed. Liver, spleen and kidney organs were excised and weight. Lipid profile parameters and indicators for liver and kidney function were determined using serum. Results: The results showed that EAC inoculation caused in addition to subcutaneous solid tumor formation, significant decrease in Body Weight, increase in organ weights, marked rise in serum concentrations of aspartate, alanine aminotransferases and gamma-glutamyl transferase (AST, ALT, GGT), urea, creatinine, uric acid, and Total cholesterol. Also, remarkable elevation in Low Density Lipoprotein / High Density Lipoprotein (LDL/HDL) ratio and triglycerides level was detected. Besides reducing tumor weight, the protective effects on BW and distant organs by MGN-3 were observed by maintaining normal BW, liver, spleen and kidney weights, ameliorating all biochemical parameters within normal values. Such results were more pronounced with Biobran nanoparticles. Conclusion: In conclusion, Nanocapsulation of MGN-3/Biobran appears promising as a chemopreventive agent against tumor progression and EAC-induced toxicity in healthy liver, kidney and spleen organs.

Biobran/MGN-3: A Promising Natural Strategy for Mitigating Kidney Damage and Immune Modulation During Etoposide Therapy

admin — Sat, 16 Aug 2025 20:08:00 +0000

Although chemotherapy is one of the pillars in cancer treatment, its side effects have extremely harmful impacts on many of the body’s organs. This study investigates the potential protective effect of the natural product, Biobran/MGN-3, against kidney damage and immune modulation caused by the chemotherapeutic agent Etoposide in rats. Etoposide impairs kidney function, demonstrated by high levels of urea, and imbalances in electrolytes Na and K, and low calcium levels. Etoposide also increased parameters reflecting oxidative stress, malondialdehyde (MDA) and nitric oxide (NO), while reduced the enzyme-mediated antioxidant defense activity, Glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT). Immunostaining of kidney tissues revealed that Etoposide caused inflammation by increasing proinflammatory cytokines IL-1β, TNF-α, and TGF-β expression. In addition, it increased apoptosis by raising levels of Bax, Caspase-3, and Cytochrome C, which was evident by qPCR. Comet assay revealed DNA damage in kidney cells following Etoposide treatment. It was evident by flow cytometry that Etoposide increased CD8, CD4, CD3, and CD19, which indicates lymphocyte infiltration into the kidney. On the other hand, Biobran/MGN-3 helped protect kidney function, lowering oxidative stress, restoring antioxidant enzyme activity, and reducing pro-inflammatory substances. Biobran/MGN-3 also counteracted the Etoposide-induced increase in Bax, Caspase-3, and Cytochrome C, lowering the cell death rate in the kidneys. Additionally, the results showed that Biobran/MGN-3 adjusted immune cell levels by increasing CD8+, CD4+, CD3+, and CD19+ cells, boosting both T-cell and B-cell activity. These findings suggest that Biobran/MGN-3 could be a helpful treatment addition to reduce kidney damage and mitigate immune impairment from Etoposide.

Rice bran arabinoxylan compound as a natural product for cancer treatment – an evidence-based assessment of the effects and mechanisms

admin — Fri, 16 Aug 2024 20:04:00 +0000

Context: Rice bran arabinoxylan compound (RBAC) is a natural immunomodulator with anticancer properties. Objective: This study critically evaluates the available evidence on the biological pathways of RBAC and its effects on cancer treatment. Methods: This secondary analysis of a scoping review includes studies evaluating the mechanisms of RBAC on healthy or malignant cells, animal models, or humans for cancer prevention or treatment. Data from randomized controlled trials on survival and quality of life outcomes were subjectd to meta analysis. Results: The evidence synthesis was based on 38 articles. RBAC exhibited antitumor properties by promoting apoptosis and restoring immune function in cancer patients to enhance inflammatory and cytotoxic responses to block tumorigenesis. RBAC works synergistically with chemotherapeutic agents by upregulating drug transport. In a clinical trial, combining RBAC with chemoembolization in treating liver cancer showed improved response, reduced recurrence rates, and prolonged survival. RBAC also augments the endogenous antioxidant system to prevent oxidative stress and protect against radiation side effects. In addition, RBAC has chemoprotective effects. Animals and humans have exhibited reduced toxicity and side effects from chemotherapy. Meta analysis indicates that RBAC treatment increases the survival odds by 4.02-times (95% CI: 1.67, 9.69) in the first year and 2.89-times (95% CI: 1.56, 5.35) in the second year. Conclusion: RBAC is a natural product with immense potential in cancer treatment. Additional research is needed to characterize, quantify, and standardize the active ingredients in RBAC responsible for the anticancer effects. More well-designed, large-scale clinical trials are required to substantiate the treatment efficacies further.